AstraZeneca (AZN.US) Q3 2026 Earnings Call
Live time: Oct 30, 2026 14:30 UTC
AstraZeneca (AZN.US) Q3 2026 Earnings Call
Live time: 10/30/2026 14:30:00 UTC
阿斯利康公司 (AZN.US) 2026 年第三季度业绩电话会
Summary
00:00
Opening Remarks by Joris Ceylon
Joris Ceylon, the Head of Investor Relations at AstraZeneca, opened the call by citing legal disclaimers about forward-looking statements and outlined the structure of the presentation, focusing on CER and non-GAAP financial measures.
02:20
CEO Pascal Soriot Business Overview
CEO Pascal Soriot reported strong Q3 2026 results, with 7% total revenue growth and core EPS growth of 14%. He highlighted continued market confidence and product success, including revenue growth of 7% and progress toward developing 20 new drugs by 2030.
10:06
CFO Aradhna Financial Results Summary
CFO Aradhna reported 7% total income growth and highlighted core gross margin of 83% despite seasonal fluctuations. Research and development expenses increased 5%, reflecting investment in pipeline advancements.
16:20
Dave Fredrick's Oncology Business Update
Dave Fredrick detailed AstraZeneca's strong oncology performance, highlighting Tagrisso's $2.1 billion Q3 revenue and impressive growth across key geographic areas. Emerging therapies, including HER2-positive treatment advances, also performed well.
21:26
Susan Galvez R&D Highlights
Susan Galvez presented clinical trial successes, including Saffron and Delphi 305 studies delivering breakthrough results, driving confidence in AstraZeneca's future pipeline sustainability by adding tremendous value to cancer therapies.
27:45
Biopharma Update by Ruud van den Bos
Ruud van den Bos reported strong biopharma performance with growth in respiratory and immunology (+11%) offsetting declines in cardiovascular and renal segments due to patent expiration impacts.
36:45
Marc Dunhill Rare Diseases Update
Marc Dunhill summarized rare disease business progress, which grew by 11% to $7.5 billion for the year. Key drugs, such as Ultomiris and Strensiq, demonstrated double-digit growth across global markets.
43:14
CEO Pascal Soriot Closing Remarks
CEO Pascal reiterated confidence in AstraZeneca's future, emphasizing pipeline strength with over 12 critical R&D advances in 2026 alone, and a multi-platform vision extending post-2030 opportunities.
46:58
Q&A: 2030 Pipeline Sustainability
CEO Pascal addressed analysts, affirming AstraZeneca's post-2030 growth potential by leveraging strong pipeline successes, particularly in transformative cell therapies and metabolic treatment innovations.
Related Notices
AstraZeneca | (6-K) Report by foreign issuer of material events
Oct 30, 2026 07:36
AstraZeneca | (6-K) Report by foreign issuer of material events
Oct 27, 2026 06:51
Recent Live Streams
Risk Disclaimer: The content on this page represents the author's personal opinions for general information purposes only and should not be used as a basis for any specific investment, business or commercial decision. It does not represent the position of Longbridge, and the platform makes no guarantees or commitments regarding the authenticity, accuracy or originality of the above content.